AZN Share Price

Open 4663.00 Change Price %
High 4783.29 1 Day 25.50 0.55
Low 4634.00 1 Week 101.50 2.21
Close 4688.00 1 Month -240.50 -4.88
Volume 2689123 1 Year 604.00 14.79
52 Week High 5505.00
52 Week Low 3680.00
AZN Important Levels
Resistance 2 4826.39
Resistance 1 4769.36
Pivot 4701.76
Support 1 4606.64
Support 2 4549.61
LON UK Most Active Stocks
LLOY 66.95 1.07%
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
IRG 0.40 -9.09%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
BAF 80.00 77.78%
BAF 80.00 77.78%
BAF 80.00 77.78%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%
More..

AstraZeneca PLC (LON: AZN)

AZN Technical Analysis 1.5
As on 25th Apr 2017 AZN Share Price closed @ 4688.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4602.74 & Sell for SHORT-TERM with Stoploss of 4730.82 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for April
1st Target up-side 5158.86
2nd Target up-side 5331.53
3rd Target up-side 5504.21
1st Target down-side 4666.14
2nd Target down-side 4493.47
3rd Target down-side 4320.79
AZN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
AZN Latest News
Buy/Sell Signals for ING Groep N.V. (ING) and AstraZeneca PLC (AZN)   USA Commerce Daily   - 24th Apr 17
AstraZeneca plc (AZN) Set to Announce Earnings on Wednesday   The Cerbat Gem   - 24th Apr 17
AstraZeneca plc (AZN) Given "Overweight" Rating at Barclays PLC   The Cerbat Gem   - 24th Apr 17
Stock Focus: Watching RSI Levels on Shares of AstraZeneca PLC (AZN.L)   The Standard   - 23rd Apr 17
AstraZeneca plc 12.8% Potential Decrease Indicated by Credit Suisse   DirectorsTalk Interviews   - 19th Apr 17
AstraZeneca plc (AZN) Shares Cross Below 200 DMA   Nasdaq   - 10th Apr 17
Drugs giant AstraZeneca's recommendation cut by Jefferies   Proactive Investors UK   - 10th Apr 17
Form 6-K ASTRAZENECA PLC For: Mar 31   StreetInsider.com   - 31st Mar 17
Form 6-K ASTRAZENECA PLC For: Mar 27   StreetInsider.com   - 27th Mar 17
AstraZeneca plc (AZN) Shares Bought by Oliver Luxxe Assets LLC   BBNS   - 22nd Mar 17
Interactive Technical Analysis Chart AstraZeneca PLC ( AZN LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AstraZeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.